Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.

Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline

Regeneron Pharmaceuticals Inc ( REGN , Financial), a leading player in the biotechnology industry, is currently trading at $780.98 with a market capitalization of $85.68 billion. The company's stock price has seen a gain of 6.67% today and an impressive 8.81% over the past four weeks.

Regeneron Pharmaceuticals Inc: A Biotech Powerhouse with High Outperformance Potential

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Regeneron (REGN) Reports Q2 Earnings: What Key Metrics Have to Say

Regeneron Pharmaceuticals Inc  (NASDAQ:REGN) reported second-quarter revenue of $10.24 per share on revenue of $3.16 billion today, blowing past analysts' expectations.

Drug Sales Surge Drives Regeneron Pharmaceuticals to Q2 Beat

Regeneron topped Wall Street's second-quarter calls Thursday, helping REGN stock retake its 200-day moving average.

Regeneron Surmounts Its 200-Day Line On A Handy Second-Quarter Beat

Regeneron (REGN) came out with quarterly earnings of $10.24 per share, beating the Zacks Consensus Estimate of $9.92 per share. This compares to earnings of $9.77 per share a year ago.

Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

Shares of Regeneron Pharmaceuticals Inc. REGN, -0.94% climbed 2.6% toward a 5-week high in premarket trading Thursday, after the biotechnology company reported second-quarter profit and revenue that rose above forecasts, amid strength in collaboration revenue. Net income rose to $968.4 million, or $8.50 a share, from $852.1 million, or $7.47 a share, in the year-ago period.

Regeneron's stock rallies after profit, revenue rise above expectations, amid a jump in collaboration revenue

Regeneron's stock rallies after profit, revenue rise above expectations, amid a jump in collaboration

Regeneron Pharmaceuticals Inc beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for eczema treatment Dupixent.

Regeneron Pharma beats profit estimates on Dupixent demand

TARRYTOWN, N.Y., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2023 and provided a business update.

Regeneron Reports Second Quarter 2023 Financial and Operating Results

Shares of Regeneron pulled back after the company received a complete response letter for Eylea. The CRL can result in a market arrival delay of 9 to 12 months for Eylea and creates a wider opening for Roche's Vabysmo. Continued erosion should be assumed for Eylea as Vabysmo continues to gain market share.

Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening

Biogen

Gilead Sciences

The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%.

Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points

TARRYTOWN, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 11th annual Regeneron Prize for Creative Innovation, a competition designed to honor exceptional talent and originality in biomedical research. Each year, Regeneron invites the nation's top research universities to nominate up-and-coming postdoctoral fellows and graduate students to pitch their "dream projects" within the field of biomedical science. Applicants outline the potentially groundbreaking research they would pursue given unrestricted access to resources and state-of-the-art technology, with finalists presenting their proposals to a committee of Regeneron's scientific leaders.

Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation

89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.

Regeneron (REGN) to Report Q2 Earnings: What's in Store?

United Therapeutics

Vertex Pharmaceuticals

The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to know the best biotech stocks that can give you great returns.

If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names

LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK , July 17, 2023 /PRNewswire/ -- Attention Regeneron Pharmaceuticals, Inc. ("Regeneron") (NASDAQ: REGN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Regeneron and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

REGN ALERT: The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws

NEW YORK , July 14, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/regeneron-class-action-loss-submission-form/?id=42093&from=4 Further details on the investigation: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Regeneron received a response letter from the FDA on June 27, 2023, declining to approve its application for an 8mg dose of aflibercept, marketed in the U.S. as Eylea.

REGN FRAUD ALERT: Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

Pfizer

When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, such as cancer and diabetes.

3 Pharma Stocks That AI is Loving in July

NEW YORK , July 13, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron") (NASDAQ: REGN) concerning possible violations of federal securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

REGN INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc.

NEW YORK , July 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Regeneron received a response letter from the FDA on June 27, 2023, declining to approve its application for an 8mg dose of aflibercept, marketed in the U.S. as Eylea.

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: REGN)

BioNTech SE

Celularity

Chimerix

Innoviva

Voyager Therapeutics

Zymeworks Inc

Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors.

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now

NEW YORK , July 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Regeneron Pharmaceuticals, Inc. ("Regeneron") (NASDAQ: REGN) violated federal securities laws. CURRENT INVESTIGATION DETAILS:The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Regeneron Pharmaceuticals Stock (REGN)